Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives
Cancer Treatment Reviews,
Год журнала:
2024,
Номер
131, С. 102845 - 102845
Опубликована: Окт. 16, 2024
Язык: Английский
Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies
Frontiers in Immunology,
Год журнала:
2025,
Номер
16
Опубликована: Апрель 1, 2025
In
solid
tumors,
the
tumor
microenvironment
(TME)
is
a
complex
mix
of
tumor,
immune,
stromal
cells,
fibroblasts,
and
extracellular
matrix.
Cytotoxic
T
lymphocytes
(CTLs)
constitute
fraction
immune
cells
that
may
infiltrate
into
TME.
The
primary
function
these
T-cells
to
detect
eliminate
cells.
However,
due
immunosuppressive
factors
present
in
TME
primarily
mediated
by
Myeloid-Derived
Suppressor
Cells
(MDSCs),
Tumor
associated
macrophages
(TAMs),
Cancer
Associated
Fibroblasts
(CAFs)
as
well
themselves,
fail
differentiate
effector
or
become
dysfunctional
are
unable
tumor.
addition,
chronic
antigen
stimulation
within
also
leads
phenomenon,
first
identified
lymphocytic
choriomeningitis
virus
(LCMV)
infection
mice,
where
exhausted
lose
their
functions.
Exhausted
(Tex)
characterized
presence
remarkably
conserved
inhibitory
receptors,
transcription
signaling
downregulation
key
molecules.
Tex
have
been
various
malignancies,
including
melanoma,
colorectal
hepatocellular
cancers.
Recent
studies
indicated
novel
strategies
reverse
T-cell
exhaustion.
These
include
checkpoint
inhibitor
blockade
targeting
programmed
cell
death
protein
1
(PD-1),
immunoglobulin
mucin-domain
containing-3
(Tim-3),
cytotoxic
T-lymphocyte
4
(CTLA-4),
combinations
different
therapies
(ICTs)
combination
ICTs
with
cytokine
co-stimulation.
this
review,
we
discuss
aspects
dysfunction
focus
on
We
believe
gaining
insight
mechanisms
exhaustion
human
tumors
will
pave
way
for
developing
therapeutic
target
potentially
re-invigorate
cancer.
Язык: Английский
Novel therapeutic approaches for non-small cell lung cancer: an updated view
Journal of drug targeting,
Год журнала:
2025,
Номер
unknown, С. 1 - 29
Опубликована: Апрель 5, 2025
Non-small
cell
lung
cancer
(NSCLC)
continues
to
be
one
of
the
leading
causes
cancer-related
mortality
globally.
Most
patients
who
undergo
surgical
procedures
may
encounter
distant
metastasis
or
local
recurrence,
necessitating
supplementary
treatments
such
as
radiation
therapy,
chemotherapy,
targeted
therapy
adjuvant
alternatives.
Recent
advancements
in
molecular
biology
and
immunotherapy
have
paved
way
for
innovative
therapeutic
approaches
that
target
specific
genetic
mutations
promote
immune
response
against
tumor
cells.
This
review
explores
emerging
therapies,
including
therapies
tyrosine
kinase
inhibitors
(TKIs)
actionable
(e.g.,
EGFR,
ALK,
ROS1),
well
role
checkpoint
(ICIs)
employ
body's
system
combat
cancer.
Additionally,
we
discuss
potential
exosome
promising
nanotherapeutic
options
treatment
NSCLC.
study
attempts
provide
a
thorough
overview
changing
landscape
NSCLC
its
implications
enhancing
patient
outcomes
by
presenting
these
techniques.
Язык: Английский
Neoadjuvant Radiochemotherapy Alters the Immune and Metabolic Microenvironment in Oral Cancer—Analyses of CD68, CD163, TGF-β1, GLUT-1 and HIF-1α Expressions
Cells,
Год журнала:
2024,
Номер
13(5), С. 397 - 397
Опубликована: Фев. 25, 2024
Background:
The
first-line
treatment
of
oral
squamous
cell
carcinoma
(OSCC)
involves
surgical
tumor
resection,
followed
by
adjuvant
radio(chemo)therapy
(R(C)T)
in
advanced
cases.
Neoadjuvant
radio-
and/or
chemotherapy
has
failed
to
show
improved
survival
OSCC.
Recently,
neoadjuvant
immunotherapy
shown
promising
therapeutic
efficacy
phase
2
trials.
In
this
context,
the
addition
and
is
being
reconsidered.
Therefore,
a
better
understanding
tumor-biologic
effects
RCT
would
be
beneficial.
current
study
was
conducted
on
retrospective
cohort
patients
who
received
for
cancer.
aim
evaluate
influence
immunological
microenvironment
(TME)
hypoxic
glucose
metabolisms.
Methods:
A
45
OSSC
tissue
samples
from
were
analyzed
before
after
(total
50.4
Gy;
1.8
Gy
5×
weekly;
Cisplatin
+
5-Fluorouracil).
Immunohistochemistry
CD68,
CD163,
TGF-β,
GLUT-1
HIF-1α
performed
using
microarrays
automated
counting.
Differences
expression
associations
with
histomorphological
parameters
(T-status,
N-status)
assessed
Mann–Whitney
U
test.
Results:
Tumor
resection
specimens
showed
significant
decrease
CD68
infiltration
increase
CD163
density.
CD68/CD163
ratio
significantly
lower
RCT,
indicating
shift
toward
M2
polarization.
expressions
RCT.
Larger
tumors
(T3/T4)
expression.
Other
biomarkers
not
associated
T-
N-status.
Conclusions:
induced
polarization
macrophages
TME.
This
change
immune
composition
favorable
may
prognostically
negative
counteract
immunotherapeutic
approaches.
addition,
decreased
indicate
reductions
metabolism
energy
response
“high
dose”
which
therapeutically
desirable.
Язык: Английский
Differences between Survival Rates and Patterns of Failure of Patients with Lung Adenocarcinoma and Squamous Cell Carcinoma Who Received Single-Fraction Stereotactic Body Radiotherapy
Cancers,
Год журнала:
2024,
Номер
16(4), С. 755 - 755
Опубликована: Фев. 12, 2024
We
investigated
the
survival
and
patterns
of
failure
in
adenocarcinoma
(ADC)
squamous
cell
carcinoma
(SCC)
early
stage
non-small
lung
cancer
(NSCLC)
treated
with
single-fraction
stereotactic
body
radiation
therapy
(SF-SBRT)
27–34
Gray.
A
single-institution
retrospective
review
patients
biopsy-proven
ADC
or
SCC
undergoing
definitive
SF-SBRT
between
September
2008
February
2023
was
performed.
The
primary
outcomes
were
overall
(OS)
disease-free
(DFS).
secondary
included
local
(LF),
nodal
(NF),
distant
(DF).
Of
292
eligible
174
had
118
carcinoma.
There
no
significant
change
any
outcome
except
failure.
Patients
significantly
more
likely
to
experience
than
(p
=
0.0081).
In
conclusion,
while
produced
similar
LF,
NF,
DFS,
OS,
higher
rate
suggests
that
ongoing
trials
SBRT
systemic
combinations
should
report
their
by
histology.
Язык: Английский
Efficacy and safety of combining radiotherapy with immune checkpoint inhibitors in patients with advanced non-small cell lung cancer: a real-world study
Immunopharmacology and Immunotoxicology,
Год журнала:
2024,
Номер
46(6), С. 861 - 871
Опубликована: Окт. 21, 2024
Background
The
significance
of
local
radiotherapy
(RT)
in
advanced
non-small-cell
lung
cancer
(NSCLC)
is
well
documented.
However,
the
advent
immunotherapy
has
raised
questions
regarding
synergistic
survival
benefits
or
potential
adverse
effects.
Язык: Английский
Immunotherapy for the elderly. Maybe the best option for lung cancer?
Cancer Treatment and Research Communications,
Год журнала:
2023,
Номер
37, С. 100762 - 100762
Опубликована: Янв. 1, 2023
Lung
cancer
is
usually
diagnosed
at
advanced
stage
and
systematic
therapy
administered.
New
current
diagnostic
techniques
such
as
the
convex-endobronchial
ultrasound,
radial
endobronchial
cone
beam
ct,
electromagnetic
navigation
robotic
bronchoscopy
provide
us
with
a
high
yield.
These
are
minimal
invasive
patients
comorbidities
chronic
obstructive
pulmonary
disease
heart
failure
can
be
adverse
effects.
All
these
sufficient
sample
for
molecular
investigation.
Since
immunotherapy
was
first
administered,
we
have
more
information
regarding
appropriate
patient
target
group.
Several
published
studies
divided
elderly
≥75
non-elderly
≤74
investigated
effects
of
different
drugs
survival.
In
our
commentary
present
on
receiving
versus
chemoimmunotherapy
in
two
groups
non-elderly.
Elderly
receive
both
combinations
without
differences
between
groups,
however;
needed
to
clarify
certain
aspects.
Язык: Английский